A series of major studies has shown that finerenone preserves kidney function, reduces cardiovascular risk, and improves survival across a much broader range of patients with chronic kidney disease (CKD) than it is currently ...
Jun 5, 2026
0
30
The American Society of Nephrology (ASN) today released its latest Kidney Health Guidance (KHG) addressing how potassium and phosphorus additives impact health risks (hyperkalemia and CKD-mineral and bone disorder) for people ...
Sep 18, 2025
0
15
A large international study has found that spironolactone, a medication for high blood pressure and heart failure, does not reduce the risk of heart-related death or hospitalizations in people with kidney failure receiving ...
Aug 14, 2025
0
29
Following priority review, the U.S. Food and Drug Administration approved Bayer's Kerendia (finerenone) for the treatment of patients with heart failure with left ventricular ejection fraction (LVEF) ≥40%.
Jul 15, 2025
0
22
Yonsei University College of Medicine-led research has shown amiloride is as effective as spironolactone in reducing systolic blood pressure (SBP) over 12 weeks in patients with resistant hypertension.
New genetic links have been discovered between genetically predicted height and an individual's likelihood of developing a range of diseases and conditions. These new data could help improve early diagnosis and risk monitoring ...
Mar 3, 2025
0
71
Potassium supplements in salt were associated with reduced rates of recurrent stroke and mortality in a large-scale cluster randomized clinical trial involving patients in rural northern China. Findings come from a subgroup ...
Mineralocorticoid receptor antagonists (MRAs) reduced the risk of cardiovascular death or heart failure (HF) hospitalization in patients with HF and reduced ejection fraction (HFrEF) and also in those with mildly reduced ...
Sep 5, 2024
0
40
Finerenone reduced the composite of total first and recurrent heart failure (HF) events (hospitalizations for HF or urgent HF visits) and cardiovascular death in patients with HF and mildly reduced or preserved ejection fraction, ...
Sep 2, 2024
0
49
Treatment with glucagon-like peptide 1 receptor agonists (GLP-1 RAs) is associated with lower rates of hyperkalemia and a lower rate of renin-angiotensin system inhibitor (RASi) discontinuation compared with treatment with ...
Aug 13, 2024
0
59
